Juan Gu*, Chang-fu Cui†, Li Yang‡, Ling Wang*, Xue-hua Jiang*
Oncology Research, Vol.28, No.6, pp. 681-682, 2020, DOI:10.3727/096504021X16137463165424
Abstract Colon cancer (CC) is the third most common cancer worldwide. Emodin is an anthraquinone-active substance that has the ability to affect tumor progression. Our study aims to explore the effects and the relevant
mechanism of emodin on the invasion and migration of CC in vitro and in vivo. In our study, we found that
emodin inhibited the invasion and migration abilities of RKO cells and decreased the expression of matrix
metalloproteinase-7 (MMP-7), MMP-9, and vascular endothelial growth factor (VEGF) in a dose-dependent
manner. Further research suggested that emodin inhibited EMT by increasing the mRNA level… More >